NILE
08 Dec 2020
NILE
NCT03682068
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)
AstraZeneca
Cancer Type | Bladder |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18+ years |
Sex | Both |
Tumour Stream | Urothelial Cancer |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2018-09-27 |
Anticipated End Date | 2022-04-27 |
Hospital | Lyell McEwin Hospital |
---|---|
Clinical Trial Coordinator | Andy Phay |
andy.phay@sa.gov.au | |
Phone | 08 8282 0833 |
Principal Investigator | Dr Christopher Hocking |
Recruitment Status | Recruiting |